Group 1: Investor Relations Activity - The meeting was categorized as a specific object survey [2] - Participants included representatives from various investment firms and individual investors [2] - The meeting took place on December 10, 2025, at the company's headquarters [2] Group 2: Purpose of the Meeting - The main objective was to understand the company's production and operational status [2]

Group 1: Health Products Business Performance - In the first half of 2025, the health products segment achieved revenue of 3.442 billion CNY, a year-on-year growth of 9.46% [2] - The segment focuses on a full-channel operation strategy, enhancing offline distribution and increasing online promotion efforts [2] - Key products include oral care toothpaste, which maintains a leading position, and hair care brand Yangyuanqing, which continues to grow driven by online sales [2][4] Group 2: Pharmaceutical Business Performance - The pharmaceutical segment reported a main business revenue of 4.751 billion CNY in the first half of 2025, with a year-on-year increase of 10.8% [5] - Sales of Yunnan Baiyao aerosol exceeded 1.453 billion CNY, showing a significant growth of over 20.9% [5] - Other traditional Chinese medicine products also saw notable growth, with sales of Qianling Jianpi Granules surpassing 100 million CNY and Pudilan Anti-inflammatory Tablets nearing 100 million CNY [5] Group 3: Traditional Chinese Medicine Resource Business - The traditional Chinese medicine resource segment generated external revenue of 914 million CNY in the first half of 2025, reflecting a year-on-year growth of approximately 6.3% [6] - The segment implements a "six unifications" operational model to enhance the traditional Chinese medicine industry chain [7] Group 4: R&D and Innovation Progress - The company emphasizes innovation-driven development, focusing on both traditional Chinese medicine and innovative drugs [8] - In the first half of 2025, the company initiated phase III clinical trials for the prostate cancer diagnostic nuclear drug project INR101, with 60 subjects enrolled [9] - The innovative drug project INR102 for prostate cancer treatment received clinical trial approval, and phase I trials have commenced [9] Group 5: Dividend Distribution - For the 2024 fiscal year, the company distributed a cash dividend of 11.85 CNY per 10 shares, totaling approximately 2.164 billion CNY [10] - The total cash dividend for 2024, including special dividends, amounted to 4.279 billion CNY, representing 90.09% of the net profit attributable to shareholders [10] - In the first half of 2025, the company distributed a cash dividend of 10.19 CNY per 10 shares, totaling 1.818 billion CNY, which accounted for 50.05% of the net profit for that period [10]

证券代码：301632 证券简称：广东建科 广东省建筑科学研究院集团股份有限公司 投资者关系活动记录表 答：公司重视科技创新和数字化转型，近三年主营业务研发费 用率呈现逐年上升趋势，主要投入于行业战略性、前沿性领域的研 发，绿色低碳科技研究等方面的研究。截至 2025 年 6 月 30 日，公 编号：2025-021 投资者关系 活动类别 ☑ 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 ☑ 现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及 人员姓名 广州泽恩投资 曹盈盈 松山创业投资 吴德有 深圳中天汇富基金管理有限公司 何佑胜 广东金豆子 马杰辉 深圳诚和昌私募基金投资有限公司 戴九侯 中金资本 刘弦 灏达投资 资香莲 乐盈(珠海)私募证券投资公司 鲍传广 东北证券 吴源恒 广州市摩星岭控股有限公司 董佳宁 广州南杰利私募基金 林小峰 广州瑞民基金 罗小明 广新基金 赖增强 中大情私募基金管理有限公司 刘剑荣 广东凯鼎投资有限公司 甄义勇 华福证券 王二鑫 润生投资 汪江涛 乐盈投资 李俊 时间 2025 年 12 月 12 日（星期五）14:00-16:30 ...

Group 1: Investor Relations Activity - The meeting was categorized as a specific object survey [2] - Participants included individual investors: Huang Kaiwei, Li Minggui, Chen Jiahe, Guo Hao, and Cui Weigang [2] - The meeting took place on December 10, 2025, at the Group's headquarters [2] Group 2: Company Overview - The main purpose of the investor relations activity was to understand the company's production and operational status [2] - Company representatives included Zhang Yu, Yang Kexin, and Yu Yang from the investor relations management team [2]

Group 1: Pharmaceutical Business Performance - In the first half of 2025, the pharmaceutical business group achieved a main business revenue of 4.751 billion yuan, a year-on-year increase of 10.8% [2] - Sales revenue of Yunnan Baiyao aerosol exceeded 1.453 billion yuan, with a significant year-on-year growth of over 20.9% [2] - Other core products, including Yunnan Baiyao plaster and capsules, also saw notable growth, contributing to the overall revenue increase [2] - Plant-based products, such as Qixue Kang oral liquid, reached sales of 202 million yuan, with a year-on-year growth of approximately 116.2% [2] Group 2: Health Product Channel Development - The company has established a comprehensive national sales team for health products, maintaining a leading market share in Yunnan Baiyao toothpaste [4] - Continuous optimization of the entire channel has strengthened traditional offline advantages while also focusing on emerging retail formats like instant retail and community group buying [4] Group 3: Traditional Chinese Medicine Cultivation Achievements - The company has implemented a precise research and transformation model for seed innovation, achieving coverage of ten major Yunnan medicinal sources [5] - The area of high-quality seed promotion has reached 90% of the annual target, with significant progress in the construction of "Yun Medicine Seed Valley" [5] - Over 7,000 acres of GAP management have been added for various medicinal herbs, integrating low-altitude economy and IoT technology [5] Group 4: Online Sales Performance - The pharmaceutical business group has expanded its online market, with O2O sales increasing by over 20% year-on-year [6] - During the 2025 "618" shopping festival, the company achieved a GMV of 254 million yuan through e-commerce platforms, attracting 48.45 million visitors [7] - Yunnan Baiyao toothpaste maintained the top market share in the domestic channel, while Yangyuan Qing ranked first in Tmall for anti-hair loss shampoo [7] Group 5: Nuclear Medicine Research Progress - The INR101 diagnostic nuclear medicine project has initiated Phase III clinical trials, with 32 research centers established and 60 subjects enrolled [8] - The INR102 therapeutic nuclear medicine project has received a clinical trial notification, with Phase I trials underway and 12 patients enrolled [8]

Funding and Investment Projects - The company plans to invest ¥68,766.42 million in the "Dingjie Intelligent Ecosystem Empowerment Platform Project," which includes the establishment of a research and training base and platform project development [2] - An additional ¥14,000 million will be allocated to supplement working capital to support daily operations and business development [2] Relationship with Existing Business - The platform project development is an upgrade based on the company's existing platform research, enhancing product functionality and application areas [3] - The training base will serve as a research facility and a center for client training and demonstrations, aiding in customer maintenance and expansion [3] Industry Development and Policy Support - The industrial sector is experiencing strong policy support for AI applications, as highlighted by the Ministry of Industry and Information Technology's initiative to implement "Artificial Intelligence + Manufacturing" actions [3] - This initiative aims to enhance industrial production efficiency, optimize processes, and promote the integration of industrial software with AI [3] Management Efficiency Measures - The company is enhancing internal management by leveraging AI technology to optimize operations, research, delivery, and marketing processes, thereby improving overall operational efficiency [3] Future Development Strategy - The company will adhere to the "Intelligent +" strategy, focusing on innovating productivity through data and intelligent technology [3] - Plans include transitioning to a platform ecosystem model, further developing the Dingjie Athena platform and new applications to provide high-value tools and environments for ISV partners and clients [3]

Group 1: Company Overview and Operations - The company has established Yichang Transportation Yangtze River Cruise Company as the investment and operation entity for the inter-provincial cruise project, with a management and marketing system already in place [2][3] - The pricing for the cruise products is projected to be between 2800-3000 RMB per person, with final pricing based on market rates for similar vessels [3] Group 2: Competitive Advantages - The first two inter-provincial cruise ships will feature five significant characteristics: advanced hardware with smart home systems, exceptional service experience through an integrated "shore service" model, unique immersive cultural experiences, optimized itineraries for a comfortable journey, and comprehensive views of the Three Gorges [4] Group 3: Future Expansion Plans - The company aims to become a leader in the Yangtze River Three Gorges tourism and a pioneer in China's inland cruise tourism, with plans to accelerate the self-construction of inter-provincial cruise ships and expand into the luxury cruise market [5] Group 4: Depreciation and Incentives - The depreciation period for both existing and upcoming inter-provincial cruise ships is set at 20 years [6] - The company has established a comprehensive incentive system for core management personnel, including dynamic annual salary incentives based on historical profit performance and additional rewards for exceeding profit targets [7][8]

Group 1: Company Overview - The company is one of the few in China capable of full-process manufacturing and service for automotive interior and exterior molds, providing comprehensive solutions from R&D to maintenance [2][3] - The main business focuses on mold manufacturing, with extensions into automotive inspection tools and automated equipment [2][3] Group 2: Market Position and Clientele - The company primarily serves well-known domestic and international automotive parts manufacturers, positioning its products in the mid-to-high-end market [3][4] - Major clients include prestigious automotive brands such as Audi, Mercedes-Benz, BMW, and Toyota, with a significant portion of sales directed towards large automotive parts suppliers [3][4] Group 3: Financial Performance - In 2024, the company achieved a revenue of approximately ¥720.67 million, with mold product revenue accounting for about 58.63%, automotive inspection tools for 10.61%, and automated equipment for 26.09% [4][5] - The gross margin for mold products is reported at 37.78%, indicating strong profitability in this segment [4][5] Group 4: Growth and Development Strategy - The company plans to expand its business based on market developments and strategic planning, with a focus on enhancing cooperation with major automotive manufacturers [5][6] - A new subsidiary, established in Thailand with an investment of approximately ¥150 million, aims to further the company's footprint in the automotive mold and packaging materials sector [5][6] Group 5: Future Outlook - The global mold manufacturing market is expected to maintain a high growth rate, driven by the increasing demand for automotive parts and the rapid development of the automotive industry [6][7] - The company is committed to continuous innovation in products and technology, aiming to enhance its competitive edge and expand into new market areas [6][7]

Company Overview - Chongqing New Aluminum Era Technology Co., Ltd. was established in December 2015 with a registered capital of 14,384.1247 million yuan. The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market in October 2024, with the stock code 301613 [2]. - The company specializes in the R&D, production, and sales of aluminum alloy components for new energy vehicle battery systems, with a complete business system covering material R&D, product design, advanced production processes, and large-scale production [2]. Product and Patent Information - The main product is the battery box, a critical component of new energy vehicle power battery systems, along with other parts like cell shells and precision structural components. As of June 30, 2025, the company holds 155 patents, including 23 invention patents [2][3]. Customer Base and Market Strategy - The company has established long-term stable partnerships with major clients such as BYD, CATL, and others, significantly improving its customer concentration risk. As of 2025, new customer orders have rapidly increased, alleviating dependency on major clients [4]. - The company has signed long-term agreements with several enterprises, ensuring a stable order volume from major clients like BYD and CATL [4]. Cost Management and Market Conditions - The company is focused on managing costs amid fluctuations in aluminum prices, planning to optimize the supply chain and enhance production efficiency to maintain profit margins [5]. - Recent revenue growth has been attributed to the widespread adoption of new energy vehicles and partnerships with leading automakers, although profit growth has lagged behind revenue growth since Q3 2025 [6]. Pricing and Product Development - The company employs a cost-plus pricing model, with a focus on customized products that do not have standard market prices due to varying customer requirements [7]. - Continuous investment in R&D and the development of new products and processes is planned to adapt to market changes and enhance competitiveness [6]. Acquisition Plans - The company is in the process of acquiring Honglian Electronics, aiming to leverage operational management experience and achieve synergies in technology, materials, and sales channels to enhance business scale and performance [8].

证券代码：300327 证券简称：中颖电子 中颖电子股份有限公司投资者关系活动记录表 编号 2025-006 | 投资者来访类别 | □分析师会议 ☑特定对象调研 | | | | --- | --- | --- | --- | | | □媒体采访 □业绩说明会 | | | | | □新闻发布会 □路演活动 | | | | | □现场参观 □其他 | | | | 参与单位名称及 | 淡然资产、燕园资管、德圣资产、中信建投、国韵投资、元藩投资、岗底斯投研、宁 | | | | 人员姓名 | 波银行、国科龙晖、 | | | | 时间 | 2025 年 12 月 12 日 | | | | 地点 | 会议室 | | | | 上市公司接待人 | 潘一德、徐洁敏 | | | | 员姓名 | 1、 公司简单介绍？ | | | | | 中颖电子成立于 1994 年，2002 起主营自主品牌的集成电路设计和销 | | | | | 售，2012 | | 年在深交所创业板上市，总部位于上海，在西安、合肥、深圳、 | | | | 香港设有分子公司。公司采用 Fabless 商业模式，主营工控级微控制芯片 | | | | （MCU）、锂电 ...